This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

This study has been terminated.
(Sponsor withdrew the study)
Sponsor:
Collaborators:
Amgen
Bristol-Myers Squibb
GlaxoSmithKline
Information provided by (Responsible Party):
Julie Ruth Gralow, University of Washington
ClinicalTrials.gov Identifier:
NCT00041470
First received: July 9, 2002
Last updated: June 19, 2017
Last verified: June 2017
  Purpose

The purposes of this are:

  • To determine the highest doses of Taxol and Navelbine that we can safely give to patients;
  • To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF;
  • To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;

Condition Intervention Phase
Breast Cancer Drug: Paclitaxel Drug: Vinorelbine Drug: Herceptin Drug: Filgrastim Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Resource links provided by NLM:


Further study details as provided by Julie Ruth Gralow, University of Washington:

Primary Outcome Measures:
  • To Measure Response Rates, Time to Progression and Survival in Patients so Treated. [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • To Measure the Qualitative and Quantitative Toxicity of This Regimen. [ Time Frame: <=18 months ]

Enrollment: 38
Study Start Date: March 2001
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Weekly paclitaxel, vinorelbine and GCSF

Weekly paclitaxel (50 mg/m2 IV) and weekly vinorelbine (20 mg/m2 IV) with daily G-CSF support and Herceptin for patients with HER-2/neu positive disease.

Paclitaxel weekly. Dose levels:

50 mg/m2, 60 mg/m2, 70 mg/m2, 80 mg/m2

Vinorelbine (Navelbine) administered one hour after paclitaxel, weekly. Dose levels:

20 mg/m2, 22.5 mg/m2, 25 mg/m2, 27.5 mg/m2

Patients who are HER-2+ and IV infusion. Herceptin 4 mg/kg IV given only on day 1 of the first cycle. Herceptin 2 mg/kg IV, maintenance dose will be given every week starting with week 2.

G-CSF (filgrastim, Neupogen) 5 mg/kg/day s.c., administered daily

Drug: Paclitaxel
50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Other Name: Taxol
Drug: Vinorelbine
20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Other Name: Navelbine
Drug: Herceptin
4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Other Name: Trastuzumab
Drug: Filgrastim
5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
Other Names:
  • G-CSF
  • Neupogen

Detailed Description:

Complete response (CR) in advanced breast cancer is an important predictor of improved survival. The largest experience reported with long-term follow-up in this regard is from M.D. Anderson Hospital, with a median survival of 33 months and 5-year survival of 19% among patients who achieved a CR with doxorubicin-based chemotherapy.19 We believe that our institutional experience to date indicates that CR rates in excess of 20% can be achieved in second-line chemotherapy from the combination of vinorelbine and a taxane, provided that G-CSF is given. For the reasons outlined, we believe that dose density is likely to be important for both classes of agents, but dose intensity may be most important for vinorelbine. Both paclitaxel and docetaxel can be given on a weekly schedule with some success, but it appears that myelosuppression is a more frequent dose-limiting toxicity on this schedule for docetaxel. For the current trial, we therefore propose to study weekly paclitaxel in combination with dose-intensive vinorelbine, utilizing continuous G-CSF support as in our prior studies. We believe that starting doses of 60 mg/m2 for paclitaxel and 20 mg/m2 for vinorelbine will be well tolerated, but our experience to date, treating 3 patients off study at these doses without G-CSF support, indicates that some will require G-CSF even at this dose level: we observed grade 4 neutropenia in 2 of the 3. Our intention in this trial is to determine the optimal dose of these two agents when continuous growth factor support is provided. We will be starting at a ratio of 0.8 for vinorelbine and 0.75 for paclitaxel (assuming 80 mg/m2/week as a "full" dose for the later agent).

It is now widely appreciated that patients with metastatic breast cancer whose tumors over express HER-2-neu demonstrate benefit from the addition of trastuzumab (Herceptin) to a chemotherapy program with paclitaxel as a single agent.20 Such patients will be allowed to receive trastuzumab in the standard dose and schedule (4 mg/kg loading dose, then 2 mg/kg/week) given IV, in addition to paclitaxel and vinorelbine. Since trastuzumab does not produce myelosuppression or neuropathy (the anticipated dose-limiting toxicities for vinorelbine and paclitaxel, respectively), and neither of these agents combined separately with trastuzumab produces unusual or severe new side effects, this should not affect the dose escalation scheme for the chemotherapeutic agents.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

PATIENT ELIGIBILITY

Inclusion Criteria:

  • Patient has stage IV, microscopically-confirmed carcinoma of the breast with histologic slides and/or blocks available for review.
  • Patient has had one or less prior regimens for metastatic disease. Prior paclitaxel by 3, 24 or 96-hour infusion is permitted as long as it did not result in any neuropathy. Prior docetaxel on an every 3-week schedule is permitted.
  • Measurable (bidimensionally) or evaluable disease.
  • Age > 18.
  • Karnofsky Performance Status > 70% (ECOG, < 2) at screen and on the first day of treatment.
  • Life expectancy > 16 weeks.
  • Prior irradiation is permitted, provided:
  • Prior irradiation does not exceed 25% of the estimated bone marrow volume. (See Appendix I)
  • Measurable/evaluable disease must exist outside the radiation field OR there must be histologic proof of progressive disease within a radiation field.
  • Informed consent must be obtained prior to registration.
  • Patients must be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis, spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or nitrosureas), or > 2 weeks from prior hormonal therapy.
  • All patients must have placement of appropriate central venous access device.
  • Tumor HER2/neu expression must be determined prior to study enrollment. Assessment may be by fluorescence in situ hydridization (FISH) assay or by immunohistochemistry (ICC). If determination is intermediate by ICC, FISH must be performed. For enrollment purposes, the phase I portion of the study will not discriminate based on HER2 status. However, documentation of patients' HER2 status will be maintained and Herceptin will be prescribed for all HER2 positive patients. The phase II portion of the study will enroll 30 patients who are documented HER2 overexpressors and 30 patients who are non-overexpressors.

Exclusion Criteria:

  • Granulocytes < 1,500/mm3.
  • Platelets < 100,000/mm3.
  • Hemoglobin < 9 gm/dl.
  • Creatinine > 2.0 mg/dl.
  • Total bilirubin > 2 mg/dl.
  • Visceral crisis characterized by rapidly progressive hepatic or lymphangitic lung metastases.
  • Medically unstable as judged by the patient's physician.
  • Pregnancy or lactation; failure to employ adequate contraception.
  • Uncontrolled CNS disease.
  • Pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer.
  • Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
  • Prior therapy with vinorelbine or prior therapy with a taxane that resulted in neuropathy.
  • Known hypersensitivity to E. coli-derived proteins, Filgrastim, or any component of the product as Neupogen® is contraindicated in such subjects.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041470

Locations
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023
Sponsors and Collaborators
University of Washington
Amgen
Bristol-Myers Squibb
GlaxoSmithKline
Investigators
Principal Investigator: Julie R. Gralow, M.D. University of Washington
  More Information

Responsible Party: Julie Ruth Gralow, Professor of Medicine, Medicine/Oncology, University of Washington
ClinicalTrials.gov Identifier: NCT00041470     History of Changes
Other Study ID Numbers: 18245
Study First Received: July 9, 2002
Results First Received: March 23, 2017
Last Updated: June 19, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Paclitaxel
Vinorelbine
Vinblastine
Albumin-Bound Paclitaxel
Trastuzumab
Lenograstim
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 21, 2017